Eversept Partners’s Krystal Biotech KRYS Stock Holding History

Eversept Partners’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-18,557	Closed	-$3.3M	–	78
2024 Q1	$3.3M	Sell	18,557 -62,241	-77%	-$8.65M	0.22%	53
2023 Q4	$10M	Sell	80,798 -27,973	-26%	-$3.1M	0.88%	25
2023 Q3	$12.6M	Buy	108,771 +2,306	+2%	+$281K	1.07%	21
2023 Q2	$12.5M	Buy	+106,465	New	+$10.9M	1.05%	22

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Eversept Partners's KRYS Position: Q2 2024 in Review

Eversept Partners sold out of Krystal Biotech (KRYS) in Q2 2024, closing a stake of 18,557 shares — an estimated $3.3M sold.

Eversept Partners first reported a position in KRYS in Q2 2023 and held it in 4 quarters. The position peaked at $12.6M in Q3 2023. 245 funds tracked by Wall St. Rank hold KRYS as of Q2 2024.

Eversept Partners reported no remaining Krystal Biotech position as of Q2 2024 after selling out during the quarter.
Eversept Partners sold 18,557 Krystal Biotech shares in Q2 2024, an estimated $3.3M.
Eversept Partners first reported a position in Krystal Biotech in Q2 2023 and held it in 4 quarters.
Eversept Partners's Krystal Biotech position peaked at $12.6M in Q3 2023.
245 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2024.

Based on Eversept Partners's 13F filing for Q2 2024, filed 14 Aug 2024.